The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn about the medication’s risk for weight loss and other adverse reactions in patients younger than 6 years of age.
This article was originally published on MedicalXpress.com
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
© 2025 SimplyWell.ca